Analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid. 2. Impact of 3-chloro group replacement on inhibition of proliferation and induction of apoptosis of leukemia and cancer cell lines

Journal of Medicinal Chemistry

Volumn 55, Issue 1, 2012, Pages 233-249

  Xia, Zebin ^a   Correa, Ricardo G ^a   Das, Jayanta K ^b   Farhana, Lulu ^b   Castro, David J ^a   Yu, Jinghua ^a   Oshima, Robert G ^a   Fontana, Joseph A ^b   Reed, John C ^a   Dawson, Marcia I ^a  

^a BURNHAM INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZOYLOXY 5 BROMOBENZONITRILE; 4 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 3 CHLOROCINNAMIC ACID; 4 IODO 2 TRIFLUOROMETHYLPHENYL BROMIDE; AMMONIA; ANTINEOPLASTIC AGENT; BROMINE; CINNAMIC ACID DERIVATIVE; ETHYL 3 CARBOMETHOXY 4 HYDROXYCINNAMIC ACID; ETHYL 3 CARBOMETHOXY 4 TRIFLUOROMETHYLSULFONYLOXYCINNAMIC ACID; ETHYL 3 CYANO 4 (TRIFLUOROMETHYLSULFONYLOXY)CINNAMIC ACID; ETHYL 3 CYANO 4 HYDROXYCINNAMIC ACID; ETHYL 4 [3' (1 ADAMANTYL) 4' BENZYLOXYPHENYL] 3 (TRIFLUOROMETHYL)CINNAMIC ACID; ETHYL 4 [3' (1 ADAMANTYL) 4' BENZYLOXYPHENYL] 3 CARBOMETHOXYCINNAMIC ACID; ETHYL 4 [3' (1 ADAMANTYL) 4' BENZYLOXYPHENYL] 3 CYANOCINNAMIC ACID; ETHYL 4 [3' (1 ADAMANTYL) 4' BENZYLOXYPHENYL] 3 METHOXYCINNAMIC ACID; ETHYL 4 [3' (1 ADAMANTYL) 4' BENZYLOXYPHENYL] 3 NITROCINNAMIC ACID; ETHYL 4 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 3 (TRIFLUOROMETHYL)CINNAMIC ACID; ETHYL 4 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 3 CARBOMETHOXYCINNAMIC ACID; ETHYL 4 BENZYLOXY 3 CARBOMETHOXYCINNAMIC ACID; ETHYL 4 BENZYLOXY 3 CYANOCINNAMIC ACID; ETHYL 4 BROMO 3 (TRIFLUOROMETHYL)CINNAMIC ACID; ETHYL 4 BROMO 3 METHOXYCINNAMIC ACID; ETHYL 4 BROMO 3 NITROCINNAMIC ACID; HYDROGEN; METHYL 2 BENZYLOXY 5 BROMOBENZOIC ACID; NITRATE; NITROGEN; ORPHAN NUCLEAR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT1 PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; LEUKEMIA CELL; MAMMARY GLAND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; SUBSTITUTION REACTION;

ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CINNAMATES; DRUG SCREENING ASSAYS, ANTITUMOR; LEUKEMIA; LIGANDS; MICE; MODELS, MOLECULAR; NEOPLASTIC STEM CELLS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEM CELLS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; WNT1 PROTEIN;

EID: 84862910323     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2011436     Document Type: Article

References (47)

1. Farhana, L.; Dawson, M. I.; Leid, M.; Wang, L.; Moore, D. D.; Liu, G.; Xia, Z.; Fontana, J. A. Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor Cancer Res. 2007, 67, 318-325
2. Zhang, Y.; Soto, J.; Park, K.; Viswanath, G.; Kuwada, S.; Abel, E. D.; Wang, L. Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth Mol. Cell. Biol. 2010, 30, 1341-1356
3. Zhang, Y.; Wang, L. Nuclear receptor SHP inhibition of Dnmt1 expression via ERRγ FEBS Lett. 2011, 585, 1269-1275
4. Kim, M.-K.; Chanda, D.; Lee, I.-K.; Choi, H.-S.; Park, K.-G. Targeting orphan nuclear receptor SHP in the treatment of metabolic diseases Expert Opin. Ther. Targets 2010, 14, 453-466
5. Billas, I. M.; Moulinier, L.; Rochel, N.; Moras, D. Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects J. Biol. Chem. 2001, 276, 7465-7474
6. Macchiarulo, A.; Rizzo, G.; Costantino, G.; Fiorucci, S.; Pellicciari, R. Unveiling hidden features of orphan nuclear receptors: The case of the small heterodimer partner (SHP) J. Mol. Graphics Modell. 2006, 24, 362-372
7. Cellanetti, M.; Gunda, V.; Wang, L.; Macchiarulo, A.; Pellicciari, R. Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP) J. Comput.-Aided Mol. Des. 2010, 24, 943-956
8. Farhana, L.; Dawson, M. I.; Dannenberg, J.-H.; Xu, L.; Fontana, J. A. SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor-κB activation, c-Fos/c-Jun expression, and cellular apoptosis Mol. Cancer Ther. 2009, 8, 1625-1635
9. Farhana, L.; Dawson, M. I.; Xia, Z.; Aboukameel, A.; Xu, L.; Liu, G.; Das, J. K.; Hatfield, J.; Levi, E.; Mohammad, R.; Fontana, J. A. Adamantyl-substituted retinoid-related molecules induce apoptosis in human acute myelogenous leukemia cells Mol. Cancer Ther. 2010, 9, 2903-2913
10. Farhana, L.; Dawson, M. I.; Murshed, F.; Fontana, J. A. Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-κB noncanonical and canonical pathway activation Cell Death Differ. 2011, 18, 164-173
11. Dawson, M. I.; Harris, D. L.; Liu, G.; Hobbs, P. D.; Lange, C. W.; Jong, L.; Bruey-Sedano, N.; James, S. Y.; Zhang, X.-K.; Peterson, V. J.; Leid, M.; Farhana, L.; Rishi, A. K.; Fontana, J. A. Antagonist analogue of 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest J. Med. Chem. 2004, 47, 3518-3536
12. Klaholz, B. P.; Renaud, J.-P.; Mitschler, A.; Zusi, C.; Chambon, P.; Gronemeyer, H.; Moras, D. Conformational adaptation of agonists to the human nuclear receptor RARγ Nat. Struct. Biol. 1998, 5, 199-202
13. Dawson, M. I.; Xia, Z.; Jiang, T.; Ye, M.; Fontana, J. A.; Farhana, L.; Patel, B.; Xue, L. P.; Bhuiyan, M.; Pellicciari, R.; Macchiarulo, A.; Nuti, R.; Zhang, X.-K.; Han, Y.-H.; Tautz, L.; Hobbs, P. D.; Jong, L.; Waleh, N.; Chao, W.-R.; Feng, G.-S.; Pang, Y.; Su, Y. Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: Effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity J. Med. Chem. 2008, 51, 5650-5662
14. Heck, R. F.; Nolley, J. P., Jr. Palladium-catalyzed vinylic hydrogen substitution reactions with aryl, benzyl, and styryl halides J. Org. Chem. 1972, 37, 2320-2322
15. Xia, Z.; Farhana, L.; Correa, R. G.; Das, J. K.; Castro, D. J.; Yu, J.; Oshima, R. G.; Reed, J. C.; Fontana, J. A.; Dawson, M. I. Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid J. Med. Chem. 2011, 54, 3793-3816
16. Wittig, G.; Schöllkopf, U. Über Triphenyl-phosphin-methylene als olefinbildende Reagenzien I Chem. Ber. 1954, 87, 1318
17. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds Chem. Rev. 1995, 95, 2457-2483
18. Freeman, A. W.; Urvoy, M.; Criswell, M. E. Triphenylphosphine-mediated reductive cyclization of 2-nitrobiphenyls: A practical and convenient synthesis of carbazoles J. Org. Chem. 2005, 70, 5014-5019
19. Naffziger, M. R.; Ashburn, B. O.; Perkins, J. R.; Carter, R. G. Diels-Alder approach for the construction of halogenated, o-nitro biaryl templates and application to the total synthesis of the anti-HIV agent siamenol J. Org. Chem. 2007, 72, 9857-9865
20. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells Oncogene 1995, 11, 493-504
21. Tang, X. H.; Gudas, L. J. Retinoids, retinoic acid receptors, and cancer Annu. Rev. Pathol. 2011, 6, 345-364
22. Gieseler, F.; Bauer, E.; Nuessler, V.; Clark, M.; Valsamas, S. Molecular effects of topoisomerase II inhibitors in AML cell lines: Correlation of apoptosis with topoisomerase II activity but not with DNA damage Leukemia 1999, 13, 1859-1863
23. Qi, H.; Ratnam, M. Synergistic induction of folate receptor β by all- trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates Cancer Res. 2006, 66, 5875-5882
24. Drach, J.; Lopez-Berestein, G.; McQueen, T.; Andreeff, M.; Mehta, K. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all- trans -retinoic acid Cancer Res. 1993, 53, 2100-2104
25. Zhang, Y.; Dawson, M. I.; Ning, Y.; Polin, L.; Parchment, R. E.; Corbett, T.; Mohamed, A. N.; Feng, K.-C.; Farhana, L.; Rishi, A. K.; Hogge, D.; Leid, M.; Peterson, V. J.; Zhang, X.-K.; Mohammad, R.; Lu, J.-S.; Willman, C.; VanBuren, E.; Biggar, S.; Edelstein, M.; Eilender, D.; Fontana, J. A. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog Blood 2003, 102, 3743-3752
26. Schmelz, K.; Sattler, N.; Wagner, M.; Lubbert, M.; Dorken, B.; Tamm, I. Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms Leukemia 2005, 19, 103-111
27. Zhou, H. R.; Shen, J. Z.; Fu, H. Y.; Ye, B. G.; Fan, L. P.; Lin, F. A. Detection of promoter methylation of p16 gene in hematological malignant cell lines by nested methylation specific polymerase chain reaction Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006, 14, 375-378
28. Koeffler, H. P.; Golde, D. W. Human myeloid leukemia cell lines: A review Blood 1980, 56, 344-350
29. Ekiz, H. A.; Can, G.; Gunduz, U.; Baran, Y. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts Hematology 2010, 15, 33-38
30. Tang, X. Y.; Wang, C. H.; Xiao, G. F. The effect of ATRA-induced leukemic cell differentiation on Brd7 gene expression in leukemia cell lines Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18, 593-596
31. Jimi, S.; Mashima, K.; Matsumoto, T.; Hara, S.; Suzumiya, J.; Tamura, K. RARα is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells Int. J. Oncol. 2007, 31, 397-404
32. Lee, H. J.; Thompson, J. E.; Wang, E. S.; Wetzler, M. Philadelphia chromosome-positive acute lymphoblastic leukemia: Current treatment and future perspectives Cancer 2011, 117, 1583-1594
33. Ru, H. Y.; Chen, R. L.; Lu, W. C.; Chen, J. H. hBUB1 defects in leukemia and lymphoma cells Oncogene 2002, 21, 4673-4679
34. Rodrigues, N. R.; Rowan, A.; Smith, M. E.; Kerr, I. B.; Bodmer, W. F.; Gannon, J. V.; Lane, D. P. p53 mutations in colorectal cancer Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7555-7559
35. Yamaguchi, T.; Katoh, I.; Kurata, S. Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitization Eur. J. Biochem. 2002, 269, 2782-2788
36. Hakimelahi, G. H.; Ly, T. W.; Yu, S.-F.; Zakerinia, M.; Khalafi-Nezhad, A.; Soltani, M. N.; Gorgani, M. N.; Chadegani, A. R.; Moosavi-Movahedi, A. A. Design and synthesis of a cephalosporin-retinoic acid prodrug activated by a monoclonal antibody-β-lactamase conjugate Bioorg. Med. Chem. 2001, 9, 2139-2147
37. Anuchapreeda, S.; Tima, S.; Duangrat, C.; Limtrakul, P. Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines Cancer Chemother. Pharmacol. 2008, 62, 585-594
38. Sugiyama, H. Cancer immunotherapy targeting Wilms tumor gene WT1 product Expert Rev. Vaccines 2005, 4, 503-512
39. Ochsenreither, S.; Fusi, A.; Busse, A.; Bauer, S.; Scheibenbogen, C.; Stather, D.; Thiel, E.; Keilholz, U.; Letsch, A. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow J. Immunother. 2010, 34, 85-91
40. Lu, Y.; Shi, T.; Wang, Y.; Yang, H.; Yan, X.; Luo, X.; Jiang, H.; Zhu, W. Halogen bonding: A novel interaction for rational drug design? J. Med. Chem. 2009, 52, 2854-2862
41. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemists guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084
42. Scheiner, S.; Kar, T.; Pattanayak, J. Comparison of various types of hydrogen bonds involving aromatic amino acids J. Am. Chem. Soc. 2002, 124, 13257-13264
43. Kovacs, A.; Varga, Z. Halogen acceptors in hydrogen bonding Coord. Chem. Rev. 2006, 250, 710-727
44. Dawson, M. I.; Xia, Z.; Liu, G.; Ye, M.; Fontana, J. A.; Farhana, L.; Patel, B. B.; Arumugarajah, S.; Bhuiyan, M.; Zhang, X.-K.; Han, Y.-H.; Stallcup, W. B.; Fukushi, J.; Mustelin, T.; Tautz, L.; Su, Y.; Harris, D. L.; Waleh, N.; Hobbs, P. D.; Jong, L.; Chao, W. R.; Schiff, L. J.; Sani, B. P. An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: Effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity J. Med. Chem. 2007, 50, 2622-2639
45. Mcbee, E. T.; Pierce, O. R.; Lowery, R. D.; Rapkin, E. Some dihalo-(trifluoromethyl)benzenes J. Am. Chem. Soc. 1951, 73, 3932-3934
46. Dabrowski, M.; Kubicka, J.; Lulinski, S.; Serwatowski, J. Halogen-lithium exchange between substituted dihalobenzenes and butyllithium: Application to the regioselective synthesis of functionalized bromobenzaldehydes Tetrahedron 2005, 61, 6590-6595
47. Molinspiration Chemoinformatics, Slovensky Grob, Slovak Republic. http://www.molinspiration.com/cgi-bin/properties (accessed February 8, 2011).